Engineered subtilisin protease degrades active KRAS in cancer cells, leading to differential cell targeting
M.E. Goldstein, Betty Chu, K.J. Carillo, John P. Orban, E.A. Toth, Thomas R. Fuerst
This paper demonstrates that engineered RASProtease degrades active KRAS in cancer cells, leading to reduced MEK-ERK signaling and significant cell death in KRAS-dependent MIA PaCa-2 cells.
bioRxiv · Mar 6, 2026 · PreprintCancer Biology